REFERENCES
1. Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: the 2026 update. J Hepatol. 2026;84:631-54.
2. Zhong BY, Fan W, Guan JJ, et al. Combination locoregional and systemic therapies in hepatocellular carcinoma. Lancet Gastroenterol Hepatol. 2025;10:369-86.
3. Li X, Li S, Li Y, et al. Thermal ablation therapy for hepatocellular carcinoma: recurrence mechanisms and intervention strategies. Hepatoma Res. 2025;11:25.
4. Hall B, Ohs Z, Dervishi M, Stevens A, Sutter C, Davidson J. Yttrium-90 combination therapies in hepatocellular carcinoma: current evidence and future directions. Hepatoma Res. 2026;12:20.
5. Yu Z, You R, Wang C, et al. A baseline-lymphocyte-subset nomogram for predicting severe immune-related adverse events in hepatocellular carcinoma patients receiving TACE plus immunotherapy. Hepatoma Res. 2025;11:29.
6. Li C, Chen L, Bao H, Wang Y, Guo J, Zhu G. Synergistic era: practice and reflection on TACE combined with systemic therapy in hepatocellular carcinoma. Hepatoma Res. 2026;12:36.
